Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval

Executive Summary

GlaxoSmithKline and Corixa's Bexxar nuclear pharmacy training program could help encourage faster uptake of the oncologic than Idec's Zevalin
Advertisement

Related Content

Genzyme Cerezyme Medicare Outpatient Payment Set At 94% Of AWP
Genzyme Cerezyme Medicare Outpatient Payment Set At 94% Of AWP
GSK Bexxar Launch Aims To Train 200 Sites By Year-End; AWP Is $32,500
Bexxar Retreatment, Leukemia Reports Among Corixa’s Phase IV Studies
Bexxar Retreatment, Leukemia Reports Among Corixa’s Phase IV Studies
GSK/Corixa Bexxar User Fee Deadline Extended To Review Safety Database
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Idec Zevalin NHL Indication Split By Accelerated/Standard Approval
Advertisement
UsernamePublicRestriction

Register

PS042091

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel